This issue of Gastroenterology presents a manuscript by Yurgelun et al1 that addresses the question of whether multigene panel testing offers “meaningful advantages over targeted criteria-based genetic testing” in patients meeting criteria for the most commonly recognized hereditary colorectal cancer (CRC) condition, Lynch syndrome (LS).1 LS accounts for 2%–4% of all CRC and is caused by germline mutations in mismatch repair genes.2,3 Identifying these high-risk patients is a major issue, because morbidity and mortality from CRC and extracolonic cancers in patients and their relatives can be decreased by early and intensive screening.